trial
as of 2026-07-01A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients
NCTId NCT03751488
at a glance
Phase 1 · Completed
Enrollment 48 (actual)
Sponsored by Luye Pharma Group Ltd.
Primary completion 2019-07-24
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
48 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2018-12-12
Primary completion
2019-07-24
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Luye Pharma Group Ltd.Lead Sponsor
Investigators
1
Amy Sun, MD PhDStudy Director
Sites
2 total
Garden Grove, United StatesBerlin, United States
Facts & assertions
4 sourced
Enrollment
48
Phase
PHASE1
Primary Completion Date
2019-07-24
Status
COMPLETED
relationships
The graph out of here
drug
drug
drug
lead_sponsor
company
indication
investigator
person